Bayer places 2 billion euro hybrid bonds
NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
Dual tranche with non-call periods of six and nine years
New blister receives RecyClass Design for Recycling certification, with phased rollout planned across 11 additional European markets in 2026–2027
Robigo’s engineered microbes for combatting Sudden Death Syndrome in soybeans match the performance of commercially available chemistries at half the cost, targeting launch in 2028 / The second product in development, targeting the #1 fungal …
U.S. FDA approves finerenone for new indication in patients with chronic kidney disease associated with type 1 diabetes
Not intended for U.S. and UK Media
Kerendia™ is the first FDA-approved treatment option in more than 30 years for adults with chronic kidney disease (CKD) associated with type 1 diabetes (T1D) / Approval addresses an important unmet need for a population at increased risk of …
U.S. FDA grants accelerated approval to Bayer’s targeted therapy sevabertinib as a first-line treatment option for adults with HER2-mutant non-small cell lung cancer
Not intended for U.S. and UK Media
Accelerated approval of sevabertinib for patients with advanced HER2-mutant non-small cell lung cancer (NSCLC) follows FDA Priority Review and Breakthrough Therapy Designations, and reflects the potential for sevabertinib to provide substantial …
Commitment aims to support the growth of winter canola in the Southern Great Plains of the U.S., as a feedstock for renewable diesel and sustainable aviation fuel
Bayer initiates Phase II study of investigational GIRK4 inhibitor in patients with atrial fibrillation
Not intended for U.S. and UK Media
GIRK4 (BAY 3670549) is an investigational highly selective G-protein-coupled inwardly rectifying potassium channel 4 (GIRK4) inhibitor being evaluated as a potential new approach to control the electrical activity of cardiomyocytes in patients …
Commercialization of two blockbusters already started, with additional launches expected over the next years / Bayer announces genome-edited standable soy and development of herbicide tolerant trait to correspond with Icafolin, a unique crop …
Phase III REVEAL Study with Investigational PET Radiotracer Iodine 124 Evuzamitide Presented as Late-Breaker at ESC 2026
Not intended for U.S. and UK Media – European Society of Cardiology (ESC) Congress 2026:
Pivotal study met primary endpoints in the assessment of sensitivity and specificity for the diagnosis of cardiac amyloidosis based on visual scan interpretation / Phase III results in patients with suspected cardiac amyloidosis were presented at …
Finerenone slowed kidney function decline and reduced kidney-cardiovascular risk versus placebo in patients with hypertensive nephropathy
Not intended for U.S. and UK Media – Late breaking data presented at ESC Congress 2026:
A pre-specified subgroup analysis of the Phase III FIND-CKD study found that finerenone slowed kidney function decline compared with placebo in addition to standard of care in patients with hypertensive nephropathy, a population for whom there …
Phase 2 GenePHIT trial successfully randomized and completed enrollment of one of the largest gene therapy trials conducted in heart failure to date, with more than 170 participants randomized across 64 sites in 12 countries1 / …